The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 3×
“…between the dimers that form the orthosteric binding site and are recognized by modulators such as cyclothiazide, aniracetam, CX614 [2 H ,3 H ,6a H -pyrrolidino (2,1-3 9 ,2 9 )1,3-oxazino(6 9 ,5 9 -5,4)benzo(e)1,4-dioxan-10-one] and the monovalent ions Cl 2 and K + (Traynelis et al., 2010).”
BackgroundMolecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 1×
“The allosteric myr-pocket inhibitors assemble the inactive conformation of Abl or BcrAbl by promoting the docking of the SH3 and SH2 domains onto the Abl kinase domain, which seems to work also for the first generation TKI resistant T 315 I mutant (Zhang et al., 2006, 2009; Fabbro et al., 2010).”
BackgroundAdenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“The isomerization of a receptor macromolecule between different conformational states.”
BackgroundmTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationStructure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA
Chandra, V., Huang, P., Hamuro, Y., Raghuram, S., Wang, Y., Burris, T. P., & Rastinejad, F. (2008) · Nature · doi:10.1038/nature07413 · Cited by 808
Self-citationEmerging paradigms in GPCR allostery: implications for drug discovery
Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498 · cited 3×
“…phenomenon of allostery as it pertains to receptors; this has already been covered in a number of prior reviews (e.g., Changeux and Edelstein, 1998, 2005; Christopoulos, 2002; Christopoulos and Kenakin, 2002; May et al., 2007; Conn et al., 2009; Changeux, 2010, 2012, 2013a; Wootten et al., 2013).”
BackgroundSelf-citation
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
Self-citationHow Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor
Ge, X., Yang, H., Bednarek, M. A., Galon-Tilleman, H., Chen, P., Chen, M., Lichtman, J. S., Wang, Y., Dalmas, O., Yin, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.016 · Cited by 376
“These data demonstrate that LEAP2 is a noncompetitive antagonist of GHSR, likely modulating the receptor through binding to an allosteric site (Christopoulos et al., 2014).”
BackgroundGABAA receptor: Positive and negative allosteric modulators
Olsen, R. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.036 · Cited by 354
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Self-citationAllosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J.-P., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 336
Self-citationStructural insights into G-protein-coupled receptor allostery
Thal, D. M., Glukhova, A., Sexton, P. M., & Christopoulos, A. (2018) · Nature · doi:10.1038/s41586-018-0259-z · Cited by 319
Self-citationBarnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Novel Allosteric Modulators of G Protein-coupled Receptors
Gentry, P. R., Sexton, P. M., & Christopoulos, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662759 · Cited by 199
“The ability to achieve unprecedented modes of on-target selectivity and/or fine-tune endogenous responses as a consequence of pure PAM or NAM activity may prove particularly important in diseases where tight physiological regulation is vital, such as neurodegeneration, schizophrenia, diabetes, and endocrine disorders.”
BackgroundInfluentialSelf-citationAllostery and biased agonism at class B G protein-coupled receptors
Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00049 · Cited by 112
Self-citationSpatiotemporal identification of druggable binding sites using deep learning
Kozlovskii, I., & Popov, P. (2020) · Communications Biology · doi:10.1038/s42003-020-01350-0 · Cited by 89
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
van der Westhuizen, E. T., Choy, K. H. C., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606656 · Cited by 63
Self-citation
Metadata
- Authors
- Christopoulos, A., Changeux, J.-P., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J.-P., Sexton, P. M., Kenakin, T. P., Ehlert, F. J., Spedding, M., & Langmead, C. J.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 66
- Issue
- 4
- Pages
- 918-947
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2134984814
- Cited by
- 238
- References
- 19
- FWCI
- 11.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.